AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Proto-oncogene serine/threonine-protein kinase mos

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P00540

UPID:

MOS_HUMAN

Alternative names:

Oocyte maturation factor mos; Proto-oncogene c-Mos

Alternative UPACC:

P00540; Q3KPG9; Q3KPH0

Background:

The Proto-oncogene serine/threonine-protein kinase mos, also known as Oocyte maturation factor mos and Proto-oncogene c-Mos, plays a pivotal role in cell cycle progression and differentiation. Its kinase activity is crucial for the meiotic phase of oocyte development, marking it as a key player in reproductive biology.

Therapeutic significance:

Understanding the role of Proto-oncogene serine/threonine-protein kinase mos could open doors to potential therapeutic strategies. Its critical function in cell cycle regulation and oocyte maturation presents a unique opportunity for targeted interventions in reproductive health and oncology.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.